Med school drug pushers

How scientists are selling out to drug companies
By DAVID S. BERNSTEIN  |  January 28, 2010

MED SCHOOL DRUG PUSHERS: Scientists are selling out to drug companies.You may have heard of a little ongoing row about a Merck drug called Vioxx, which was pulled from the market in 2004 due to evidence that it caused serious heart problems in some users. According to the allegations, Merck aggressively marketed Vioxx as safe and effective for pain relief, while repressing knowledge that the drug raised the risk of heart attack. This week, another plaintiff won a multi-million-dollar jury award; 9650 more lawsuits nationwide are still pending.

What you may not know is that one of Merck’s most effective allies in marketing Vioxx was Marvin A. Konstam, a professor of medicine at Tufts University, chief of cardiology at Tufts-affiliated New England Medical Center (NEMC), and a paid consultant for Merck. In 2001 — a year after serious questions about Vioxx’s safety came to light — Konstam was the lead author of an article in the journal Circulation that found “no evidence” that Vioxx caused more cardiovascular problems than alternative pain medicines or placebos. The article was cited in dozens of other articles.

It also offered evidence, some say, of how Boston’s prestigious medical institutions — one of the area’s biggest assets — are being used and abused by pharmaceutical and medical-device companies to market their products.

Why? Because Konstam himself did not actually conduct or oversee any clinical trials for the 2001 article: the data was all provided to him by Merck from the company’s own trials. Nor did Konstam decide which trial results were included in the study: that, too, was handled by Merck, and critics allege that its findings were flawed. (The article, however, is not implicated in current lawsuits.) Five Merck employees were listed as co-authors of the study. The article’s acknowledgments cited Qinfen Yu for doing the data analysis, without mentioning that Yu was also a Merck employee. It also thanked Diana Rogers for “preparation of the manuscript,” omitting that she was a ghostwriter hired by Merck. Despite all this, the first author you see on the article is Marvin A. Konstam, and the first institutional name is NEMC. Only in the fine print do you find the co-authors’ Merck affiliation.

This is increasingly how medical research is getting done these days. Drug and medical-device companies conceive, finance, manage, and even write projects. Then they enlist researchers with affiliations that are trusted as independent intellectual authorities — such as Harvard Medical School, Brigham and Women’s, or Dana Farber — to put their names on the articles. When conducted in this manner, medical research is sometimes little more than marketing garbed in lab coats.

Scientists lend their names to such studies for any number of reasons: for the prestige of publishing (sometimes in quest of tenure), to land a grant, to maintain a lucrative consulting relationship with the company, or simply out of genuine scientific interest in the subject matter. Critics say these scientists usually don’t see themselves as willing instruments of pharma/biotech sales-and-marketing teams. But there is little doubt that the companies see them that way.

1  |  2  |  3  |  4  |  5  |  6  |  7  |  8  |   next >
Related: The underdog, 2010 Muzzle Awards on campus, Heading for health, More more >
  Topics: News Features , Science and Technology, Technology, Massachusetts General Hospital,  More more >
| More

Most Popular
Share this entry with Delicious
  •   MRS. WARREN GOES TO WASHINGTON  |  March 21, 2013
    Elizabeth Warren was the only senator on the Health, Education, Labor, and Pensions (HELP) Committee, aside from the chair and ranking minority, to show up at last Thursday's hearing on indexing the minimum wage to inflation.
  •   MARCH MADNESS  |  March 12, 2013
    It's no surprise that the coming weekend's Saint Patrick's Day celebrations have become politically charged, given the extraordinary convergence of electoral events visiting South Boston.
  •   LABOR'S LOVE LOST  |  March 08, 2013
    Steve Lynch is winning back much of the union support that left him in 2009.
  •   AFTER MARKEY, GET SET, GO  |  February 20, 2013
    It's a matter of political decorum: when an officeholder is running for higher office, you wait until the election has been won before publicly coveting the resulting vacancy.
    It wasn't just that Scott Brown announced he was not running in the special US Senate election — it was that it quickly became evident that he was not handing the job off to another Republican.

 See all articles by: DAVID S. BERNSTEIN